Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2015

View Archived Issues

First-in-human results presented for LY-3023414

CD-133-targeted oncolytic adenovirus therapy shows promising preclinical results

Grant supports Adenovir's development of second-generation drug for epidemic keratoconjunctivitis

Medical Developments agrees to term sheet for European distribution of Penthrox

Bavarian Nordic confirms option exercise by U.S. Government for Filovirus vaccine

Almirall returns Kappaproct rights to InDex

New ultra-long-acting insulin analogue with improved PK/PD profile

Threshold Pharmaceuticals begins phase II study of TH-4000 in NSCLC

Novartis reports phase I results for INC-280 plus erlotinib

Nuclea Biotechnologies partners with Aelan Cell Technologies in epigenetics field

CytRx's new LADR technology platform expected to expand oncology pipeline

The Dana-Farber Cancer Institute discloses kinase inhibitors

First-in-human clear images of glioblastoma patients using [18F]AA-7

Roche provides initial update from phase IIb trial of sembragiline in Alzheimer's disease

Clovis Oncology begins rolling NDA submission for rociletinib

ALS groups fund two phase II studies focused on biomarkers

Preclinical and first-in-human data of BI-655064 as a CD40 inhibitor

Spiolto Respimat approved in first European countries for COPD

Yervoy receives approval for unresectable malignant melanoma in Japan

University of Tsukuba patent describes orexin OX2 receptor agonists

Roche and Chugai present BTK inhibitors

P2X4 negative modulators for pain in early development at Sunovion

Ajinomoto divulges AJS-1669 for type 2 diabetes

FDA approves Tuxarin ER

FDA grants approval to Orkambi for cystic fibrosis

Lilly's GLP-1 receptor agonist Trulicity Ateos approved in Japan

Boehringer Ingelheim's Ofev receives approval for IPF in Japan

Harvoni approved in Japan for genotype 1 HCV

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...